

#14
DAS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fukumura et al.

Appl. No.: 09/843,922

Filing Date: April 30, 2001

Title: Negative-Sense RNA Virus Vector for
Nerve Cell



RECEIVED

Art Unit: 1636

NOV 25 2002

Examiner: Mary Benton TECH CENTER 1600/2900

Atty. Docket: 4001-0003CIP

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

2. The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. § 1.17(p).

3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(i)(1).

a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

b. I hereby certify that no item of information on this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

4. Relevance of the non-English language document(s) is discussed in the present specification. See pages _____ of the specification of the present application.

5. The document(s) was/were cited in a corresponding foreign application. A copy of a search report issued in the foreign application is attached. An English language version of the foreign search report is attached for the Examiner's information. M.P.E.P. § 609 (A)(3).

6. A concise explanation of the relevance of the non-English language document(s) is attached hereto or appears below.

7. The Examiner's attention is directed to co-pending U.S. Patent Application No. ____ , filed ____ , which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

8. Copies of the documents were cited by or submitted to the Office in Application No. ____ , filed ____ , which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

9. Other:

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. **50-0622**.

Respectfully submitted,

SHANKS & HERBERT

By: 
Shelly Guest Cermak
Reg. No. 39,571

Date: 11-22-02

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314
703-683-3600

FORM PTO 1449		ATTY. DOCKET NO. 4001-0003CIP	APPLICATION NO. 09/843,922
<u>INFORMATION DISCLOSURE STATEMENT</u>		APPLICANT(S) Masayuki Fukumura, et al.	
		FILING DATE April 30, 2001	GROUP 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1		NOV 22 2002				
	AE1						NOV 25 2002
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

RECEIVED

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM1						<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN1						<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO1						<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP1						<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Grifman M., et al., "Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis", <i>Proc. Natl. Acad. Sci. USA</i> , 95(23), pp. 13935-13940 (1998)		
AS	1			
AT	1			

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.